BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 567 filers reported holding BIO-TECHNE CORP in Q4 2021. The put-call ratio across all filers is 0.60 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $125,453 | -27.3% | 1,843 | -12.9% | 0.00% | -33.3% |
| Q2 2023 | $172,647 | +23.9% | 2,115 | +12.6% | 0.01% | +20.0% |
| Q1 2023 | $139,329 | -38.8% | 1,878 | -31.6% | 0.01% | -50.0% |
| Q4 2022 | $227,588 | +22.4% | 2,746 | +319.9% | 0.01% | +11.1% |
| Q3 2022 | $186,000 | -20.9% | 654 | -3.4% | 0.01% | -18.2% |
| Q2 2022 | $235,000 | -32.3% | 677 | -13.6% | 0.01% | -21.4% |
| Q1 2022 | $347,000 | -17.4% | 784 | -3.4% | 0.01% | -12.5% |
| Q4 2021 | $420,000 | +23.5% | 812 | +15.7% | 0.02% | +14.3% |
| Q3 2021 | $340,000 | +23.6% | 702 | +14.9% | 0.01% | +16.7% |
| Q2 2021 | $275,000 | +26.7% | 611 | +7.6% | 0.01% | +20.0% |
| Q1 2021 | $217,000 | +34.0% | 568 | +11.4% | 0.01% | +11.1% |
| Q4 2020 | $162,000 | +52.8% | 510 | +19.2% | 0.01% | +28.6% |
| Q3 2020 | $106,000 | +5.0% | 428 | +11.2% | 0.01% | 0.0% |
| Q2 2020 | $101,000 | +94.2% | 385 | +39.0% | 0.01% | +75.0% |
| Q1 2020 | $52,000 | -3.7% | 277 | +11.7% | 0.00% | 0.0% |
| Q4 2019 | $54,000 | +145.5% | 248 | +119.5% | 0.00% | +100.0% |
| Q3 2019 | $22,000 | -15.4% | 113 | -8.9% | 0.00% | -33.3% |
| Q2 2019 | $26,000 | +4.0% | 124 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $25,000 | +47.1% | 124 | 0.0% | 0.00% | +50.0% |
| Q4 2018 | $17,000 | -46.9% | 124 | -21.0% | 0.00% | -50.0% |
| Q3 2018 | $32,000 | +23.1% | 157 | -12.8% | 0.00% | 0.0% |
| Q2 2018 | $26,000 | +8.3% | 180 | +11.1% | 0.00% | 0.0% |
| Q1 2018 | $24,000 | +14.3% | 162 | 0.0% | 0.00% | +33.3% |
| Q4 2017 | $21,000 | +5.0% | 162 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $20,000 | +100.0% | 162 | +97.6% | 0.00% | +50.0% |
| Q2 2017 | $10,000 | -44.4% | 82 | -50.0% | 0.00% | 0.0% |
| Q1 2017 | $18,000 | +50.0% | 164 | +35.5% | 0.00% | -33.3% |
| Q4 2016 | $12,000 | – | 121 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |